Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease
Launched by VERTEX PHARMACEUTICALS INCORPORATED · Jan 23, 2025
Trial Information
Current as of October 03, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called Inaxaplin (IXP) to see how well it works and how safe it is for people with a specific type of kidney disease known as proteinuric APOL1-mediated kidney disease. This condition can lead to kidney damage, and the researchers want to find out if Inaxaplin can help improve kidney function in affected individuals.
To participate, you need to be between the ages of 65 and 74 and have a specific genetic makeup (APOL1 genotype) that makes you more susceptible to this kidney disease. Additionally, your kidney function, measured by something called the estimated glomerular filtration rate (eGFR), should be at least 25 mL/min. If you join the trial, you can expect to undergo regular check-ups to monitor your health and kidney function while taking the medication. The trial is currently recruiting participants, and if you have any questions or think you might be eligible, it's a good idea to discuss it with your healthcare provider.
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Participant has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay
- • Estimated Glomerular Filtration Rate (eGFR) of greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73m\^2 at screening
- Key Exclusion Criteria:
- • Evidence of Focal Segmental Glomerulosclerosis (FSGS) with a known cause other than due to APOL1 risk variants
- • Uncontrolled hypertension
- • Other protocol defined Inclusion/Exclusion criteria may apply.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a global biotechnology company dedicated to the innovation and development of transformative therapies for serious diseases, particularly those with significant unmet medical needs. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex specializes in the research and commercialization of treatments for cystic fibrosis and other genetic disorders. Leveraging cutting-edge science and a commitment to patient-centric solutions, Vertex collaborates with healthcare professionals and researchers to advance clinical trials and bring groundbreaking therapies to market, aiming to improve the lives of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Mississippi, United States
Tupelo, Mississippi, United States
Columbia, South Carolina, United States
Baton Rouge, Louisiana, United States
Lauderdale Lakes, Florida, United States
Laurelton, New York, United States
Huntsville, Alabama, United States
Lawrenceville, Georgia, United States
Columbus, Georgia, United States
Houston, Texas, United States
Metairie, Louisiana, United States
New Bern, North Carolina, United States
Shreveport, Louisiana, United States
Chapel Hill, North Carolina, United States
Spartanburg, South Carolina, United States
Cary, North Carolina, United States
New York, New York, United States
Silver Spring, Maryland, United States
Dallas, Texas, United States
Dallas, Texas, United States
Dallas, Texas, United States
Las Vegas, Nevada, United States
Norfolk, Virginia, United States
Fayetteville, Georgia, United States
Savannah, Georgia, United States
Newark, New Jersey, United States
Orlando, Florida, United States
Hollywood, Florida, United States
Dallas, Texas, United States
New Orleans, Louisiana, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported